Can a Diabetic Medication offer Cardiovascular benefits?

Within the past 20 years, the number of available classes of medications for treatment of Type 2 diabetes mellitus (T2DM) has drastically increased. In the evaluation of these anti-hyperglycemic agents, the longterm effects on cardiovascular safety have become as important as the glucose lowering effects themselves. Novel therapies are required to prove their safety, without clinically meaningful increases in the rates of major adverse cardiovascular events (MACE).